Friday, Jan 25, 2019
Using Telemedicine HCV Care Model in Prisons in SPAIN
“HCV telemedicine program satisfying, cost-effective in Spanish prison: A telemedicine program brought high levels of satisfaction and proved cost effective in patients with hepatitis C in a Spanish prison, according to data presented at The Liver Meeting 2018…” Read more about Spain’s prison-based HCV “Telemedicine” treatment model.
Saturday in Surrey! Visit HepCBC booth at January 26th Surrey Health Expo
Come visit HepCBC’s “Liver Wellness” info table at the “Surrey Health Expo” on Saturday, January 26, 2019 between noon and 5 pm. It is at Surrey City Hall, 13450 – 104 Avenue in Surrey. Please stop by to say hello to our volunteers. The organizers generously donated HepCBC a 2-page spread in “South Asian Health” magazine plus the space for our booth. Come, enjoy, and support this great annual event with us.
Using Nurse-led HCV Care Model in Prisons in AUSTRALIA
“Nurse-led HCV care model results in 95% or higher SVR rates in prison: A decentralized, nurse-led model of hepatitis C care with direct-acting antivirals was significantly effective and led to high levels of sustained virologic response in a large cohort of inmates, according to a recently published study.” Read more about Australia’s prison-based “Nurse-Led” and “Sexual Health Service” treatment models.
Free CME-certified WEBINARS on Fatty Liver Disease Jan. 29-31, 2019
HepCBC is quite interested in NASH [Non-alcoholic steatohepatitis] because people with hepatitis C are particularly vulnerable to NASH, even after being cured of hepatitis C! Register for a free CCO webinar January 29th, 30th, or 31st: “Identifying and Managing NASH in High-Risk Populations: A Silent Epidemic.” Targets physicians seeking CMO credits, but anyone can register.
New Study Shows Potential Benefits of Screening All New Cancer Patients for Hepatitis
Study of 3051 patients determined prevalence of chronic HBV, HCV, and HIV infection among patients with newly-diagnosed cancer. A high proportion of those detected with viral hepatitis in this screening were newly-diagnosed (42.1% of the chronic hep B and 31% of the hep C), suggesting that hepatitis B and hepatitis C screening of all those newly-diagnosed with cancer “may be warranted”, though screening them for HIV probably is not.